Suchergebnisse - "Casper, Corey"

PubPharm (11)

1

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes

enthalten in: Blood advances | 2023

von Pierson, S. | Lim, M. | Srkalovic, G. | +13

2

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

enthalten in: British journal of haematology | 2021

von van Rhee, F. | Rossi, J. | Simpson, D. | +10

3

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease : a prespecified, open-label, extension analysis of two trials

enthalten in: The Lancet. Haematology | 2020

von van Rhee, F. | Casper, C. | Voorhees, P. | +4

4

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

enthalten in: Blood | 2018

von van Rhee, F. | Voorhees, P. | Dispenzieri, A. | +39

CommentIn: Blood. 2018 Nov 15;132(20):2109-2110. - PMID 30442745

5

The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease

enthalten in: Brain, behavior, and immunity | 2017

von Sun, Y. | Wang, D. | Salvadore, G. | +9

6

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

enthalten in: Oncotarget | 2015

von van Rhee, F. | Casper, C. | Voorhees, P. | +7

7

Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2015

von Casper, C. | Chaturvedi, S. | Munshi, N. | +9

8

Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab

enthalten in: The patient | 2015

von van Rhee, F. | Rothman, M. | Ho, K. | +8

9

Siltuximab for multicentric Castleman's disease : a randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Oncology | 2014

von van Rhee, F. | Wong, R. | Munshi, N. | +19

ErratumIn: Lancet Oncol. 2014 Sep;15(10):417

10

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2013

von Kurzrock, R. | Voorhees, P. | Casper, C. | +14